Michael Manning, MD
Allergy & Immunology · Scottsdale, AZNPI 1396744249
Payments from drug & device makers
Across 3,369 payments — averaging $955.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$944K
- GSK$280K
- Takeda Pharmaceuticals U.S.A., Inc.$271K
- Novartis$260K
- Regeneron$212K
- Shire North American Group Inc$167K
- plus $1.1M from 38 others
Across 32 payments — averaging $1100.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$35K
What the payments were for
- Consulting fees$154,54514%
- Speaking & faculty fees$829,17277%
- Travel & lodging$63,0476%
- Food & beverage$33,1203%
- Education$3210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,217,532 in reported general payments places this provider in the 95th percentile of 90 allergy & immunology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 71 | $3,683,076 |
| RuconestC1 Esterase Inhibitor, Recomb | 13 | $3,663,503 |
| Dupixent SyringeDupilumab | 30 | $149,396 |
| TezspireTezepelumab-Ekko | 35 | $146,935 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $137,174 |
| HyqviaIgg/Hyaluronidase,recombinant | 30 | $95,425 |
| XolairOmalizumab | 17 | $80,789 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $72,469 |
| NucalaMepolizumab | 14 | $52,078 |
| Spiriva RespimatTiotropium Bromide | 48 | $47,386 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $26,148 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $24,126 |
| OpzeluraRuxolitinib Phosphate | 11 | $21,857 |
| Advair HfaFluticasone Propion/Salmeterol | 39 | $16,470 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 55 | $12,374 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro, Hyqvia | $271,243 | $3,778,501101 claims |
| Pharming Healthcare, Inc.Ruconest | $141,020 | $3,663,50313 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $156,474 | $182,778100 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $279,500 | $158,276178 claims |
| CSL BehringHizentra | $944,113 | $137,17413 claims |
| Genentech, Inc.Xolair | $48,904 | $80,78917 claims |
| Boehringer IngelheimSpiriva Respimat | $148 | $47,38648 claims |
| Incyte CorporationOpzelura | $18 | $21,85711 claims |
| Optinose US, Inc.Xhance | $503 | $11,99215 claims |
| MerckDulera | $83,636 | $10,51414 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $13,856 | $6,27722 claims |
| PfizerPaxlovid | $4,876 | $012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 90 allergy & immunology providers in Arizona.
Other allergy & immunology in Scottsdale
- Jennifer HillScottsdale$418K
- Jean NelsonScottsdale$183K
- Kiranjit KhalsaScottsdale$150K
- Sanjay PatelScottsdale$21K
- Hiral ThakrarScottsdale$19K
- Rachael StillwagonScottsdale$7K
- Rebecca KoenigsbergScottsdale$3K
- Aaron DavisScottsdale$3K
- Matthew RankScottsdale$1K
- Connie HsuLitchfield Park$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.